Phosphoinositide 3-kinases (PI3Ks) are important signalling enzymes in most cell types. Recent gene targeting studies have shed light on the importance of this family of lipid kinases in the immune system, and the complex mechanisms by which these kinases are regulated in vivo. We have recently reported a phenotype of mice in which the p110δ PI3K catalytic subunit was inactivated by point mutation. In the present paper, we compare and contrast the phenotypes of p110δ mutant mice with those of mice that lack p85α or p110γ , and discuss these in the context of PI3K signalling in B-and T-cells.
Introduction
Class IA phosphoinositide 3-kinases (PI3Ks) are heterodimeric proteins consisting of a p110 catalytic subunit, and a p85, p55 or p50 regulatory subunit. There are three genes that encode the catalytic subunits p110α, p110β and p110δ, and three genes that encode at least five catalytic subunits, p85α, p55α, p50α, p85β and p55γ [1] . Each of the catalytic subunits can bind to any of the regulatory subunits. The regulatory subunits have SH2 domains that bind phosphorylated tyrosines in the context of Tyr-Xaa-Xaa-Met motifs. Upon recruitment to the inner leaflet of the plasma membrane, p110 phosphorylates phosphatidylinositol (4,5)-bisphosphate (PIP 2 ) on the D3 position to yield phosphatidylinositol (3,4,5)-trisphosphate (PIP 3 ) [1] . In B-cells, PI3Ks are activated by recruitment to phosphorylated TyrXaa-Xaa-Met motifs in the cytoplasmic domains of CD19 [2] and BCAP (B-cell adaptor protein) [3] , whereas in T-cells, PI3K may be activated by recruitment to phosphorylated Tyr-Xaa-Xaa-Met motifs in TRIM [T-cell receptor (TcR)-interacting molecule] [4] and CD28 [5] . Other proteins with Tyr-Xaa-Xaa-Met sequences that are expressed in B-and T-cells include Gab and IRS (insulin receptor substrate) family proteins. Recent evidence also suggests that Vav controls PI3K activation in B-and T-cells [6, 7] . In addition, Ras and Rac may also have a role in PI3K activation [8] [9] [10] . However, the exact details of how PI3K is regulated in B-and T-cells remain to be elucidated.
Within the cell, there is a diverse set of proteins with pleckstrin homology (PH) domains that bind to PIP 3 and, consequently, are recruited to the plasma membrane upon activation of PI3Ks [11] . These proteins are, in turn, responsible for the activation of many different signalling pathways. A prominent member of this family is the Ser/Thr kinase Akt/protein kinase B (PKB), whose activation is strictly PI3K-dependent, and which has been shown to transmit many of the PI3K signals [12] . In B-and T-cells, the PH domain-containing Tec-family tyrosine kinases [including Tec, Btk (Bruton's tyrosine kinase) and Itk] are also important mediators of PI3K signalling, since they control the release of calcium into the cytosol by phosphorylating phospholipase C (PLC)γ isoforms [13] . Together, PH-domain-containing signal transducers control cell growth, differentiation, proliferation, apoptosis, metabolism, intracellular trafficking and migration [14] .
In recent years, the use of gene targeting has helped to elucidate the complex roles of PI3K in the immune system [14] [15] [16] [17] [18] . In the present paper, we explore how recent evidence points to a central role for p110δ in the activation of B-and T-cells, and review these data in light of previously reported studies on PI3K knockouts. A summary of the phenotypes that will be discussed is presented in Table 1 . 
Targeting the p85 regulatory subunit
The regulatory subunits p85α, p55α and p50α are expressed by alternative splicing of the same gene. Two complementary gene-targeting strategies were employed to investigate the in vivo role for these gene products. Suzuki et al. [19] deleted the first exon, such that p85α could no longer be expressed, but the p55α and p50α were retained; these mice are referred to as p85α −/− (Table 1) . In contrast, Fruman et al. [20] targeted the last five exons of the p85α gene, such that the expression of all three isoforms was abolished; these mice are referred to as (p85α/p55α/p50α) −/− ( Table 1 ). The mice generated by Suzuki et al. [19] were viable (although some succumbed to infections), whereas the mice generated by Fruman et al. [20] died shortly after birth, with a few exceptions. Fruman et al. [20] hence used a RAG (recombinationactivating gene) complementation approach to investigate Band T-cell function in (p85α/p55α/p50α) −/− mice. Interestingly, both groups found defects in B-cell development and function, but no T-cell defects. Specifically, the transition from pro-to pre-B-cells was partially blocked, and both groups found that the number of mature B-cells was reduced by 50-80%. CD5
+ peritoneal B-1 cells were absent in (p85α/p55α/p50α) −/− mice, but were detected at approx. 60% of normal levels in p85α −/− mice, suggesting that this B-cell subset is particularly sensitive to the amount of available PI3K activity. Proliferation of B-cells in response to B-cell receptor (BcR) triggering (using anti-IgM) or anti-CD40 stimulation was impaired in both knockouts; however, Fruman et al. [20] found that anti-CD40, in combination with interleukin (IL) 4, could induce a normal proliferative response. Suzuki et al. [19] reported that T-cell-independent, but not T-cell-dependent, antibody production was impaired. Further analysis of p85α knockout cells revealed reduced expression of each of the p110 catalytic subunits, but increased expression of p85β (and p50α in the Suzuki study) [19] [20] [21] .
It should be noted that, in other tissues, PI3K signalling downstream of insulin was enhanced and sustained for longer than in wild-type cells [22, 23] . These results indicate that the p85 knockouts cannot necessarily be considered PI3K knockouts; rather, the regulation of PI3K activity has been disrupted, resulting in potentially diminished PI3K signalling in some instances, and enhanced signalling in other contexts. The molecular basis for this discrepancy is not well understood. One possibility arises from the observation that p85 inhibits the kinase activity of the associated p110 subunit. This inhibition is released by the binding of the p85 Src homology 2 (SH2) domains to phosphotyrosine peptides [24] . Therefore, if p110 monomers are expressed in p85 knockout cells, these may be hyperactive, and may provide enhanced signalling despite their reduced expression levels [25] . Not only does p85 suppress p110 activity, but it interferes with the capacity of Ras to activate p110 [26] ; therefore, free p110 subunits may also be more sensitive to activation by Ras. Another explanation that has been put forward to explain the increased PI3K activity found in some p85 knockout cells is that cells contain a molar excess of free (i.e. non-p110-bound) p85 subunits that act as dominant-negative proteins that bind non-productively to receptors [27, 28] . Removal of some of these subunits (p85β is still expressed in p85α knockout cells), would thus provide greater access to receptors for the remaining p85-p110 heterodimers. However, neither of these hypotheses explain why anti-IgM-stimulated signalling is impaired, while insulin receptor signalling is enhanced in p85 knockout mice.
Targeting the class IA catalytic subunits p110α and p110β knockout mice have also been generated and are both embryonically lethal [29, 30] , thus the effects of these mutations on immune cells could not be determined. Since p110δ expression is largely restricted to cells of the immune system [31, 32] , we considered the possibility that, among the three class IA p110 isoforms, p110δ might contribute to unique aspects of B-and T-cell biology. To explore this possibility, we introduced a point mutation of Asp 910 → Ala (D910A) in p110δ by gene targeting, resulting in a loss-offunction locus while retaining the expression of the protein [33] . We chose this strategy, rather than introducing a deletion in the p110δ gene, as we reasoned that the loss of p110δ expression could lead to compensation by p110α and p110β.
In p110δ D910A/D910A B-cells, anti-IgM-induced Akt/PKB phosphorylation was almost completely lost, and calcium flux was attenuated, suggesting that p110δ is the principle PI3K that signals downstream of the BcR (Table 1) . Consistent with this observation, proliferation of p110δ D910A/D910A B-cells in response to anti-IgM stimulation was fully abrogated. In addition, both T-cell-dependent and T-cellindependent (type II) immune responses were attenuated, and marginal zone B-cells and CD5 + B1 cells were nearly undetectable. This B-cell phenotype was similar to that of the p85α knockout mice, but with two important exceptions: p110δ D910A/D910A B-cells have reduced proliferation in response to anti-CD40, in combination with IL4, and T-cell-dependent antibody production was impaired. T-cells provide help for B-cells by expressing the CD40 ligand on their surface and by secreting IL4. The reduced responsiveness of p110δ D910A/D910A B-cells to these stimuli might therefore explain the impairment of the T-celldependent B-cell immune response. However, the story is more complicated than this: in contrast with p85α knockout mice, the p110δ D910A/D910A mice also show impaired T-cell function.
In p110δ D910A/D910A T-cells, Akt/PKB phosphorylation, following triggering of the TcR by anti-CD3 antibodies, was almost ablated and calcium flux was attenuated, indicating that p110δ is also the main provider of PI3K activity downstream of the TcR. The T-cells in the thymus appeared to be normal, but the spleens of the p110δ D910A/D910A mice contained reduced numbers of T-cells. Upon closer inspection, these T-cells had a more 'naïve' phenotype, as judged by reduced expression of CD44 and elevated expression of CD62L (L-selectin). Activated and memory T-cells upregulate CD44 to facilitate adhesion to the extracellular matrix, whereas CD62L expression is required for the homing of naïve T-cells to the high endothelial venules in lymph nodes [34] . These results suggested that T-cells in p110δ D910A/D910A mice develop normally, but fail to mature or survive in the periphery. In vitro, p110δ D910A/D910A T-cells showed reduced proliferation in response to anti-CD3 stimulation, but proliferated robustly in response to combined anti-CD3 and anti-CD28 treatment. The T-cells also produced normal levels of IL2 in response to anti-CD3 and anti-CD28 antibodies, even though Akt/PKB phosphorylation in response to both CD3 and CD28 stimulation were diminished (K. Okkenhaug and A. Bilancio, unpublished work). These results seem to indicate that, rather than transmitting costimulatory signals by activating PI3K, CD28 stimulation can bypass the requirement for PI3K stimulation. Consistent with this notion, a Tyr → Phe mutant of CD28 that cannot bind PI3K retains the capacity to co-stimulate proliferation and IL2 production. In contrast, PI3K activity is required by CD28 to promote survival via up-regulation of Bcl-X L [35] [36] [37] .
However, not all aspects of CD3 and CD28 co-stimulation were normal in p110δ D910A/D910A mice: the p110δ D910A/D910A
T-cells showed reduced capacity to recruit lipid rafts when stimulated with anti-CD3 and anti-CD28 antibody-coated polystyrene beads. The formation of lipid rafts, which depends on co-stimulatory signals provided by CD28, is thought to act as a 'signal amplifier' during T-cell-antigenpresenting cell interactions [38] . Therefore, responses to low-affinity peptide antigens, where lipid rafts may have a critical amplifier function, may well be impaired, even in the presence of CD28 co-stimulatory signals. Evidence for this was obtained by crossing the p110δ D910A/D910A mice with a TcR transgenic strain, in which all the T-cells recognize an ovalbumin peptide (Ova), presented by MHC class II molecules. p110δ D910A/D910A Ova-TcR transgenic T cells showed a diminished response to the Ova peptide presented by B-cells (which express the CD28 ligand, B7), both with respect to proliferation and IL2 production. Therefore, in an in vivo context, T-cell activation in p110δ D910A/D910A mice is likely to be attenuated, even in the presence of co-stimulation. CD4 + T-cells not only promote immune responses, but can also suppress inflammation. Indeed, inflammation of the bowel is frequently observed in knockout mice with deficient T-cell responses [39] . In this context, it was of interest to find that the p110δ D910A/D910A mice develop a mild form of inflammatory bowel disease (IBD) [33] . Also of relevance to this finding is that the gene for human p110δ, PIK3CD, maps to the IBD7 susceptibility locus on chromosome 1p36 [40] (OMIM 605225).
Clayton et al. [41] have analysed B-cell responses from mice in which p110δ expression was abrogated by gene deletion; these mice are referred to as p110δ −/− (Table 1) . They utilized a novel assay to quantify PIP 3 production, without prior radiolabelling of the cells [42] , to demonstrate that, in the absence of p110δ, anti-IgM stimulation no longer leads to PIP 3 production. Many of the phenotypes were similar to those of the p110δ D910A/D910A mice: defective Akt/PKB phosphorylation, attenuated calcium flux, lack of marginal zone and B1 cells, and severely reduced T-dependent and T-independent-2 antibody responses. In addition, the nuclear factor-κB pathway, leading to Bcl-X L expression, was impaired. Activation of Btk and PLCγ 2 were also shown to be impaired in p110δ −/− B-cells. Some differences between the p110δ −/− and p110δ D910A/D910A mice were apparent, however: the failure to proliferate in response to polyclonal anti-IgM F(ab ) 2 antibody was less pronounced in p110δ −/− B-cells than in p110δ D910A/D910A B-cells. In addition, p110δ −/− spleen cells from adult mice contained near normal numbers of B-and T-cells, whereas p110δ D910A/D910A spleen cell numbers were reduced by approx. 50%. Clayton et al. [41] did not report whether or not T-cell activation was affected in p110δ −/− mice. The apparently milder phenotype of the p110δ −/− mice, compared with the p110δ D910A/D910A mice, implies that abrogating expression of the p110δ catalytic subunit might allow for some compensatory signalling by p110α and/or p110β. It will be of interest to determine to what extent T-cell signalling is affected in p110δ −/− mice.
p110γ transmits signals downstream of Gprotein-coupled receptors (GPCRs) in T-cells
In contrast with p110α, p110β and p110δ, p110γ associates with a p101 regulatory subunit, and is activated by GPCRs [43, 44] . Like p110δ, p110γ expression is mainly restricted to leucocytes. The main phenotype of p110γ −/− mice appears to involve migration of cells of the innate immune system, such as neutrophils, macrophages and certain populations of mast cells [45] [46] [47] . However, Sasaki et al. [46] also reported a T-cell defect: p110γ −/− T-cells showed reduced proliferation and IL2 production to various stimuli, and p110γ −/− mice had impaired T-cell-dependent immune responses in vivo.
The signalling lesion in p110γ −/− T-cells has not been identified, but seems unlikely to involve the TcR itself [46] . Rather, deficiencies in the antigen-presenting cells and/or impaired responsiveness to factors in the serum, both in vivo and in vitro, may impair p110γ −/− T-cells to respond to TcR stimulation. For instance, lipid mediators such as lysophosphatidic acid signal through GPCRs and can control T-cell proliferation and survival [48, 49] . Thymocytes from p110γ −/− mice showed increased susceptibility to the induction of apoptosis by adenosine A2A (a GPCR antagonist), but not in response to anti-CD3 stimulation [46] . These data indicate that p110γ contributes to T-cell activation and/or survival, but, in contrast with p110δ, p110γ may not contribute directly to antigen-receptor signalling.
Concluding remarks
Gene-targeting studies have identified p110δ and p110γ as non-redundant mediators of PI3K signalling in the immune system. This increased understanding of how PI3K signalling is controlled in the immune system has major potential clinical implications for the treatment of autoimmunity, transplant rejection and leukaemia, and opens the way for the development drugs that may help to alleviate these health problems.
